Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $20 | $14 | $18 |
| G&A Expenses | $0 | $4 | $4 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19 | $25 | $18 | $25 |
| Operating Income | -$19 | -$25 | -$18 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $14 | $11 | -$19 |
| Pre-Tax Income | -$17 | -$11 | -$6 | -$44 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$11 | -$6 | -$45 |
| % Margin | – | – | – | – |
| EPS | -0.226 | -0.15 | -0.084 | -0.75 |
| % Growth | -50.9% | -78.1% | 88.8% | – |
| EPS Diluted | -0.226 | -0.15 | -0.08 | -0.75 |
| Weighted Avg Shares Out | 77 | 77 | 77 | 60 |
| Weighted Avg Shares Out Dil | 77 | 77 | 77 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $18 | $0 |
| EBITDA | -$17 | -$25 | -$6 | -$44 |
| % Margin | – | – | – | – |